Citigroup
RBOT

Citigroup’s Vicarious Surgical RBOT Stock Holding History

Citigroup’s Portfolio RBOT Stock Details RBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5
Closed -$66 – 5892
2024
Q4 		$66 Sell
5
-2
-29% -$21 ﹤0.01% 5705
2024
Q3 		$40 Sell
7
-300
-98% -$1.99K ﹤0.01% 5574
2024
Q2 		$1.8K Sell
307
-449
-59% -$4.02K ﹤0.01% 5341
2024
Q1 		$6.84K Buy
756
+253
+50% +$3.02K ﹤0.01% 5276
2023
Q4 		$5.53K Buy
503
+502
+50,200% +$5.6K ﹤0.01% 5318
2023
Q3 		$21 Sell
1
-695
-100% -$25.3K ﹤0.01% 5580
2023
Q2 		$38.2K Buy
696
+659
+1,781% +$42K ﹤0.01% 4773
2023
Q1 		$2.55K Sell
37
-13
-26% -$1.01K ﹤0.01% 5062
2022
Q4 		$3.02K Sell
50
-15
-23% -$1.39K ﹤0.01% 5143
2022
Q3 		$7K Sell
65
-73
-53% -$8.51K ﹤0.01% 5121
2022
Q2 		$12K Sell
138
-321
-70% -$39.2K ﹤0.01% 5281
2022
Q1 		$69K Buy
459
+312
+212% +$58K ﹤0.01% 4594
2021
Q4 		$47K Buy
+147
New +$51.8K ﹤0.01% 5101

Other funds holding RBOT

VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
DP
DDD Partners Bellevue, Washington $1.45B AUM 9.14% 1-Year Est. Return
MAMHA
MY.Alpha Management HK Advisors Hong Kong $246M AUM 73.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AMH
Aspex Management (HK) Central, Hong Kong $6.9B AUM 28.37% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DnB Asset Management
DnB Asset Management Oslo, Norway $28B AUM 26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's RBOT Position: Q1 2025 in Review

Citigroup sold out of Vicarious Surgical (RBOT) in Q1 2025, closing a stake of 5 shares — an estimated $66 sold.

Citigroup first reported a position in RBOT in Q4 2021 and held it in 13 quarters. The position peaked at $69K in Q1 2022. 31 funds tracked by Wall St. Rank hold RBOT as of Q1 2025.

  • Citigroup reported no remaining Vicarious Surgical position as of Q1 2025 after selling out during the quarter.
  • Citigroup sold 5 Vicarious Surgical shares in Q1 2025, an estimated $66.
  • Citigroup first reported a position in Vicarious Surgical in Q4 2021 and held it in 13 quarters.
  • Citigroup's Vicarious Surgical position peaked at $69K in Q1 2022.
  • 31 funds tracked by Wall St. Rank held Vicarious Surgical as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.